Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy
BJU International · 2024-04 · 133 (S4) · 14-22
DOI: 10.1111/bju.16207 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 08.11.2023. Verfasst von Bart Geboers und 21 weiteren Autor:innen. Beteiligte Einrichtung: Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Multiparametric Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To evaluate the additional value of prostate‐specific membrane antigen positron emission tomography (PSMA‐PET) to conventional diagnostic tools to select patients for hemi‐ablative focal therapy (FT). Patients and Methods We performed a retrospective analysis on a multicentre cohort (private and institutional) of 138 patients who underwent multiparametric magnetic resonance imaging (mpMRI), PSMA‐PET, and systematic biopsies prior to radical prostatectomy between January 2011 and July 2021. Patients were eligible when they met the consensus criteria for FT: PSA 0.5 mm or seminal vesicle involvement at final histopathology. The diagnostic accuracy of mpMRI, systematic biopsies and PSMA‐PET for csPCa (separate and combined) was calculated within a four‐quadrant prostate model by receiver‐operating characteristic and 2 × 2 contingency analysis. Additionally, we assessed whether the diagnostic tools correctly identified patients suitable for hemi‐ablative FT.
Results
In total 552 prostate quadrants were analysed and 272 (49%) contained csPCa on final histopathology. The area under the curve, sensitivity, specificity, positive predictive value and negative predictive value for csPCa were 0.79, 75%, 83%, 81% and 77%, respectively, for combined mpMRI and systematic biopsies, and improved after addition of PSMA‐PET to 0.84, 87%, 80%, 81% and 86%, respectively ( P < 0.001). On final histopathology 46/138 patients (33%) were not suitable for hemi‐ablative FT. Addition of PSMA‐PET correctly identified 26/46 (57%) non‐suitable patients and resulted in 4/138 (3%) false‐positive exclusions.
Conclusions
Addition of PSMA‐PET to the conventional work‐up by mpMRI and systematic biopsies could improve selection for hemi‐ablative FT and guide exclusion of patients for whom whole‐gland treatments might be a more suitable treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW, Australia.
- St. Vincent's Prostate Cancer Research Centre, Sydney, NSW, Australia.
- Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands.
- Department of Urology, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands.
- Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, NSW, Australia.
- Department of Urology, St. George Hospital, Sydney, NSW, Australia.
ORCID-Profile: Bart Geboers, Dennie Meijer, Alexandar Blazevski, James Thompson, Paul Doan, Matthijs J Scheltema, Phillip D Stricker
Zitieren
APA
Geboers, B., Meijer, D., Counter, W., Blazevski, A., Thompson, J., Doan, P., Gondoputro, W., Katelaris, A., Haynes, A. M., Delprado, W., O'Neill, G., Yuen, C., Vis, A. N., van Leeuwen, P. J., Ho, B., Liu, V., Lee, J., Donswijk, M. L., Oprea-Lager, D., …, & Stricker, P. D. (2024). Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy. BJU International, 133(S4), 14-22. https://doi.org/10.1111/bju.16207
Vancouver
Geboers B, Meijer D, Counter W, Blazevski A, Thompson J, Doan P, et al. Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy. BJU International. 2024;133(S4):14-22. doi:10.1111/bju.16207
BibTeX
@article{Geboers2024,
author = {Geboers, Bart and Meijer, Dennie and Counter, William and Blazevski, Alexandar and Thompson, James and Doan, Paul and Gondoputro, William and Katelaris, Athos and Haynes, Anne-Maree and Delprado, Warick and O'Neill, Gordon and Yuen, Carlo and Vis, Andre N and van Leeuwen, Pim J and Ho, Bao and Liu, Victor and Lee, Jonathan and Donswijk, Maarten L and Oprea-Lager, Daniela and Scheltema, Matthijs J and Emmett, Louise and Stricker, Phillip D},
title = {Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy},
journal = {BJU International},
year = {2024},
volume = {133},
number = {S4},
pages = {14--22},
doi = {10.1111/bju.16207}
}
EUVIMED